BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• 

  HIV

  Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries

  In coordination with the United States President’s Emergency Plan for AIDS Relief, Gilead will make its twice-yearly HIV prophylactic Yeztugo available to resource-limited countries “at no profit.”

  September 5, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study

  Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to Dupixent, according to analysts at Leerink Partners.

  September 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Monarez Blasts Partisan Public Health Policy at CDC Under RFK Jr.

  Ousted CDC Director Susan Monarez claimed in an op-ed published in The Wall Street Journal Thursday that she was fired for refusing to rubber-stamp COVID-19 recommendations to be made by an advisory panel that has expressed “antivaccine rhetoric.”

  September 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  China

  Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+

  Hengrui Pharmaceuticals has been busy this year, signing a nearly $2 billion cardio contract with Merck in March and a 12-asset agreement with GSK in July worth up to $12 billion.

  September 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Psychedelics

  With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’

  Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies, which founded Lykos, bemoaned a “moving of the goal posts” in Lykos’ rejection but looked for positives in the newly released complete response letter.

  September 5, 2025

   · 

  3 min read

   · 

  Dan Samorodnitsky
• 

  Government

  Senate Hearing Devolves Into Theater as Kennedy Accused of Breaking Vaccine Promises

  Robert F. Kennedy Jr. repeated a series of anti-vaccine talking points during his appearance in front of the Senate finance committee on Thursday, as Democratic and Republican senators alike hammered the Health Secretary on recent COVID-19 vaccine restrictions and his views on Operation Warp Speed.

  September 5, 2025

   · 

  4 min read

   · 

  Dan Samorodnitsky
• Press Releases

  HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

  September 5, 2025

   · 

  8 min read
• Press Releases

  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - September 4, 2025

  September 5, 2025

   · 

  2 min read
• Press Releases

  Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 4, 2025

  September 5, 2025

   · 

  1 min read
• Press Releases

  Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

  September 5, 2025

   · 

  5 min read